Opin­ion: A place­bo-con­trolled tri­al re­quire­ment from CMS will spell the end of Bio­gen's con­tro­ver­sial Alzheimer's drug

With just $3 mil­lion in 2021 sales for Bio­gen’s con­tro­ver­sial new Alzheimer’s drug, $225 mil­lion in Aduhelm in­ven­to­ry sit­ting on shelves, and hun­dreds of mil­lions in Aduhelm ex­pens­es com­ing, Bio­gen will soon be at a cross­roads.

And that means dump­ing Aduhelm may be the com­pa­ny’s best op­tion.

While Bio­gen might not yet be pub­licly sig­nal­ing that the end of Aduhelm is nigh, it’s dif­fi­cult to see how the com­pa­ny can keep spend­ing so much on a drug with very lit­tle prospect for com­mer­cial suc­cess over the next 4-plus years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER